Gabapentin Strides 400 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

gabapentin strides 400 mg kapseli, kova

strides pharma (cyprus) limited - gabapentin - kapseli, kova - 400 mg - gabapentiini

Gabapentin Strides 300 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

gabapentin strides 300 mg kapseli, kova

strides pharma (cyprus) limited - gabapentin - kapseli, kova - 300 mg - gabapentiini

Gabapentin Strides 100 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

gabapentin strides 100 mg kapseli, kova

strides pharma (cyprus) limited - gabapentin - kapseli, kova - 100 mg - gabapentiini

Vancomycin Strides 125 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

vancomycin strides 125 mg kapseli, kova

strides pharma (cyprus) limited - vancomycin hydrochloride - kapseli, kova - 125 mg - vankomysiini

Vancomycin Strides 250 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

vancomycin strides 250 mg kapseli, kova

strides pharma (cyprus) limited - vancomycin hydrochloride - kapseli, kova - 250 mg - vankomysiini

OXALIPLATIN STRIDES 5 mg/ml infuusiokuiva-aine, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

oxaliplatin strides 5 mg/ml infuusiokuiva-aine, liuosta varten

strides arcolab international limited - oxaliplatinum - infuusiokuiva-aine, liuosta varten - 5 mg/ml - oksaliplatiini

MITOXANTRONE STRIDES 2 mg/ml infuusiokonsentraatti, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

mitoxantrone strides 2 mg/ml infuusiokonsentraatti, liuosta varten

strides arcolab international limited - mitoxantroni hydrochloridum - infuusiokonsentraatti, liuosta varten - 2 mg/ml - mitoksantroni

Kauliv Euroopan unioni - suomi - EMA (European Medicines Agency)

kauliv

strides pharma (cyprus) limited - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Edistride Euroopan unioni - suomi - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflosiinipropaanidiolimonohydraatti - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetilla käytettävät lääkkeet - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. lisäksi muiden lääkkeiden hoitoon tyypin 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

IRINOTECAN MYLAN 20 mg/ml infuusiokonsentraatti, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

irinotecan mylan 20 mg/ml infuusiokonsentraatti, liuosta varten

mylan hospital as - irinotecani hydrochloridum trihydricum - infuusiokonsentraatti, liuosta varten - 20 mg/ml - irinotekaani